Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line

GLIA

Volumn 43, Issue 2, 2003, Pages 104-118

  Frohnert, Paul W ^a   Stonecypher, Mark S ^a   Carroll, Steven L ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Glial growth factor; Malignant peripheral nerve sheath tumor; Neurofibromatosis; SMDF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FORSKOLIN; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; NEURITE PROMOTING FACTOR; PROTEIN TYROSINE KINASE; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; MITOGENESIS; NERVE SHEATH TUMOR; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SCHWANN CELL; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; AXOTOMY; BLOTTING, NORTHERN; CELL DIVISION; CELLS, CULTURED; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FORSKOLIN; IMMUNOBLOTTING; MALE; NERVE TISSUE PROTEINS; NEUREGULIN-1; NUCLEASE PROTECTION ASSAYS; PRECIPITIN TESTS; PYRIMIDINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHWANN CELLS; SIGNAL TRANSDUCTION; THYMIDINE; TIME FACTORS; TRITIUM;

EID: 0042092519     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10232     Document Type: Article

References (80)

1. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, DiFiore PP, Kraus MH. 1995. Cooperative signaling of erbB3 and erbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821.
2. Anderson LM, Hagiwara A, Kovatch RM, Rehm S, Rice JM. 1989. Transplacental initiation of liver, lung, neurogenic and connective tissue tumors by N-nitroso compounds in mice. Fundam Appl Toxicol 12:604-620.
3. Badache A, Muja N, DeVries GH. 1998. Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 17:795-800.
4. Bargmann CI, Weinberg RA. 1988. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7:2043-2052.
5. Bargmann CI, Hung MC, Weinberg RA. 1986a. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657.
6. Bargmann CI, Hung MC, Weinberg RA. 1986b. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230.
7. Birindelli S, Perrone F, Oggionni M, Lavarino C, Pasini B, Vergani B, Ranzani GN, Pierotti MA, Pilotti S. 2001. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest 81:833-844.
8. Brockes JP, Fields KP, Raff MC. 1979. Studies on cultured Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 165:105-118.
9. Brockes JP, Lemke GE, Balzer DR Jr. 1980. Purification and preliminary characterization of a glial growth factor from the bovine pituitary. J Biol Chem 255:8374-8377.
10. Brockes JP, Breakefield XO, Martuza RL. 1986. Glial growth factor-like activity in Schwann cell tumors. Ann Neurol 20:317-322.
11. Buzard GS, Enomoto T, Anderson LM, Perantoni AO, Devor DE, Rice JM. 1999. Activation of neu by missense point mutation in the transmembrane domain in schwannomas induced in C3H/HeNCr mice by transplacental exposure to N-nitrosoethylurea. J Cancer Res Clin Oncol 125:653-659.
12. Carraway KLI, Cantley LC. 1994. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8.
13. Carroll SL, Miller ML, Frohnert PW, Kim SS, Corbett JA. 1997. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 17:1642-1659.
14. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
15. Conley FK, Rubinstein LJ, Spence AM. 1976. Studies on experimental malignant nerve sheath tumors maintained in tissue and organ culture systems. II. Electron microscopy observations. Acta Neuropathol (Berl) 34:293-310.
16. DeClue JE, Heffelfinger S, Benvenuto G, Ling B, Li S, Rui W, Vass WC, Viskochil D, Ratner N. 2000. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 105:1233-1241.
17. Di Marco E, Pierce JH, Knicley CL, Di Fiore PP. 1990. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol 10:3247-3252.
18. Diwan BA, Rehm S, Rice JM. 1996. Age- and dose-dependent transplacental carcinogenesis by N-nitrosoethylurea in Syrian golden hamsters. J Cancer Res Clin Oncol 122:643-652.
19. Dong Z, Brennan A, Liu N, Yarden Y, Lefkowitz G, Mirsky R, Jessen KR. 1995. Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation and maturation of rat Schwann cell precursors. Neuron 15:585-596.
20. Druckrey H, Ivankovic S, Preussmann R. 1966. Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats. Nature 210:1378-1379.
21. Engele J, Schubert D, Bohn MC. 1991. Conditioned media derived from glial cell lines promote survival and differentiation of dopaminergic neurons in vitro: role of mesencephalic glia. J Neurosci Res 30:359-371.
22. Fischbach GD, Rosen KM. 1997. ARIA: a neuromuscular junction neuregulin. 429-458.
23. Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, Zhou H, Bridges AJ. 1997. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem Pharmacol 54:877-887.
24. Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C. 2000. A dual role of erbB2 in myelination and in expansion of the Schwann cell precursor pool. J Cell Biol 148:1035-1046.
25. Gerecke KM, Wyss JM, Karavanova I, Buonanno A, Carroll SL. 2001. ErbB transmembrane tyrosine kinase receptors are differentially expressed throughout the adult rat central nervous system. J Comp Neurol 433:86-100.
26. Grinspan JB, Marchionni MA, Reeves M, Coulaloglou M, Scherer SS. 1996. Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci 16:6107-6118.
27. Gutmann DH. 2001. The neurofibromatoses: when less is more. Hum Mol Genet 10:747-755.
28. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. 1997. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51-57.
29. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL. 1994. Insect cell-expressed p180ErbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91:8132-8136.
30. Hadjiargyrou M, Patterson PH. 1995. An anti-CD9 monoclonal antibody promotes adhesion and induces proliferation of Schwann cells in vitro. J Neurosci 15:574-583.
31. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang W-J, Wood WI, Goeddel DV, Vandlen RL. 1992. Identification of heregulin, a specific activator of p185erbB2. Science 256:1205-1210.
32. Hudziak RM, Schlessinger J, Ullrich A. 1987. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163.
33. Jones EL, Searle CE, Smith WT. 1973. Tumours of the nervous system induced in rats by the neonatal administration of N-ethyl-N-nitrosourea. J Pathol 109:123-139.
34. Katoh M, Yazaki Y, Sugimura T, Terada M. 1993. c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine kinase. Biochem Biophys Res Commun 192:1189-1197.
35. Kimura H, Fischer WH, Schubert D. 1990. Structure, expression and function of a schwannoma-derived growth factor. Nature 348:257-260.
36. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI. 1989. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58:287-292.
37. Kourea HP, Orlow I, Scheithauer BW, Cordon-Cardo C, Woodruff JM. 1999. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol 155:1855-1860.
38. Krasnoselsky A, Massay MJ, DeFrances MC, Michalopoulos G, Zarnegar R, Ratner N. 1994. Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J Neurosci 14:7284-7290.
39. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE. 2002. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 62:4507-4513.
40. Marchionni MA, Goodearl ADJ, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBurney RN, Waterfield MD, Stroobant P, Gwynne D. 1993. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312-318.
41. Marikovsky M, Lavi S, Pinkas-Kramarski R, Karunagaran D, Liu N, Wen D, Yarden Y. 1995. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Oncogene 10:1403-1411.
42. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A. 2001. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20:97-105.
43. Matheny C, DiStefano PS, Milbrandt J. 1992. Differential activation of NGF receptor and early response genes in neural crest-derived cells. Brain Res Mol Brain Res 13:75-81.
44. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP, Barker DF, Ledbetter DH, Kleider A, Martuza RL, Gusella JF, Seizinger BR. 1990. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 87:5435-5439.
45. Mizisin AP, Li L, Perello M, Freshwater JD, Kalichman MW, Roux L, Calcutt NA. 1996. Polyol pathway and osmoregulation in JS1 Schwann cells grown in hyperglycemic and hyperosmotic conditions. Am J Physiol 270:F90-F97.
46. Mizisin AP, Li L, Calcutt NA. 1997. Sorbitol accumulation and transmembrane efflux in osmotically stressed JS1 schwannoma cells. Neurosci Lett 229:53-56.
47. Morrissey TK, Levi ADO, Nuijens A, Sliwkowski MX, Bunge RP. 1995. Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. Proc Natl Acad Sci U S A 92:1431-1435.
48. Muthuswamy SK, Muller WJ. 1995. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11:271-279.
49. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. 1999. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 155:1879-1884.
50. Nikitin AY, Ballering LAP, Lyons J, Rajewsky MF. 1991a. Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Proc Natl Acad Sci U S A 88:9939-9943.
51. Nikitin AY, Lennartz K, Pozharisski KM, Rajewsky MF. 1991b. Rat model of the human "Triton" tumor: direct genetic evidence for the myogenic differentiation capacity of schwannoma cells using the mutant neu gene as a cell lineage marker. Differentiation 48:33-42.
52. Nikitin AY, Jin JJ, Papewalis J, Prokopenko SN, Pozharisski KM, Winterhager E, Flesken-Nikitin A, Rajewsky MF. 1996. Wild type neu transgene counteracts mutant homologue in malignant transformation of rat Schwann cells. Oncogene 12:1309-1317.
53. Parada LF. 2000. Neurofibromatosis type 1. Biochim Biophys Acta 1471:M13-M19.
54. Peles E, Yarden Y. 1993. Neu and its ligands: from an oncogene to neural factors. BioEssays 15:815-824.
55. Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. 1993. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J 12:961-971.
56. Perry A, Roth KA, Banerjee R, Fuller CE, Gutmann DH. 2001. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 159:57-61.
57. Perry A, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, Watson MW, Gutmann DH. 2002. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 61:702-709.
58. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. 1996. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem 271:19029-19032.
59. Raff MC, Abney E, Brockes JP, Hornby-Smith A. 1978. Schwann cell growth factors. Cell 15:813-822.
60. Rahmatullah M, Schroering A, Rothblum K, Stahl RC, Urban B, Carey DJ. 1998. Synergistic regulation of Schwann cell proliferation by heregulin and forskolin. Mol Cell Biol 18:6245-6252.
61. Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HDH, Winters RT, Denny WA. 1998. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methyl-amino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J Med Chem 41:742-751.
62. Ross JS, Fletcher JA. 1998. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413-428.
63. Rubinstein LJ, Conley FK, Herman MM. 1976. Studies on experimental malignant nerve sheath tumors maintained in tissue and organ culture systems. I. Light microscopy observations. Acta Neuropathol 34:277-291.
64. Ryan JJ, Klein KA, Neuberger TJ, Leftwich JA, Westin EH, Kauma S, Fletcher JA, DeVries GH, Huff TJ. 1994. Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 37:415-432.
65. Schorey JS, Li Q, McCourt DW, Bong-Mastek M, Clark-Curtiss JE, Ratliff TL, Brown EJ. 1995. A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Infect Immun 63:2652-2657.
66. Schroering A, Carey DJ. 1998. Sensory and motor neuron-derived factor is a transmembrane heregulin that is expressed on the plasma membrane with the active domain exposed to the extracellular environment. J Biol Chem 273:30643-30650.
67. Schubert D, Heinemann S, Carlisle W, Tarikas H, Kimes B, Patrick J, Steinbach JH, Culp W, Brandt BL. 1974. Clonal cell lines from the rat central nervous system. Nature 249:224-227.
68. Shah NM, Marchionni MA, Isaacs I, Stroobant P, Anderson DJ. 1994. Glial growth factor restricts mammalian neural crest stem cells to a glial fate. Cell 77:349-360.
69. Sherman L, Sleeman JP, Hennigan RF, Herrlich P, Ratner N. 1999. Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro. Oncogene 18:6692-6699.
70. Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Matsumura T. 1995. Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett 95:79-83.
71. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. 1999. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18:2149-2164.
72. Tzahar E, Yarden Y. 1998. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377:M25-M27.
73. Urich H, Tien RD. 1998. Tumors of the cranial, spinal and peripheral nerve sheaths. In: Bigner DD, McLendon RD, Bruner JM, editors. Russell and Rubinstein's pathology of tumors of the nervous system. 6th ed. New York: Oxford University Press. p 141-193.
74. Wallace MR, Rasmussen SA, Lim IT, Bray BA, Zori RT, Muir D. 2000. Culture of cytogenetically abnormal Schwann cells from benign and malignant NF1 tumors. Genes Chromosomes Cancer 27:117-123.
75. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W, Ullrich A. 1995. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275.
76. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI. 1989. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230-231.
77. Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Janssen AM, Ben-Baruch N, Trollinger DB, Jacobsen VL, Meng S-Y, Lu HS, Hu S, Chang D, Yang W, Yanigahara D, Koski RA, Yarden Y. 1994. Structural and functional aspects of the multiplicity of neu differentiation factors. Mol Cell Biol 14:1909-1919.
78. Yarden Y, Sliwkowski M. 2001. Untangling the erbB signaling network. Nat Rev Mol Cell Biol 2:127-137.
79. Zanazzi G, Einheber S, Westreich R, Hannocks M-J, Bedell-Hogan D, Marchionni M, Salzer JL. 2001. Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol 152:1289-1299.
80. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A, Yoshinaga SK. 1996. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271:3884-3890.